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Abstract
Background: Recent publications suggest that neoplastic initiation and growth are dependent on a small subset of cells,
termed cancer stem cells (CSCs). Anaplastic Thyroid Carcinoma (ATC) is a very aggressive solid tumor with poor prognosis,
characterized by high dedifferentiation. The existence of CSCs might account for the heterogeneity of ATC lesions. CD133
has been identified as a stem cell marker for normal and cancerous tissues, although its biological function remains
unknown.
Methodology/Principal Findings: ATC cell lines ARO, KAT-4, KAT-18 and FRO were analyzed for CD133 expression. Flow
cytometry showed CD133pos cells only in ARO and KAT-4 (6469% and 57612%, respectively). These data were confirmed by
qRT-PCR and immunocytochemistry. ARO and KAT-4 were also positive for fetal marker oncofetal fibronectin and negative
for thyrocyte-specific differentiating markers thyroglobulin, thyroperoxidase and sodium/iodide symporter. Sorted ARO/
CD133pos cells exhibited higher proliferation, self-renewal, colony-forming ability in comparison with ARO/CD133neg.
Furthermore, ARO/CD133pos showed levels of thyroid transcription factor TTF-1 similar to the fetal thyroid cell line TAD-2,
while the expression in ARO/CD133neg was negligible. The expression of the stem cell marker OCT-4 detected by RT-PCR
and flow cytometry was markedly higher in ARO/CD133pos in comparison to ARO/CD133neg cells. The stem cell markers c-
KIT and THY-1 were negative. Sensitivity to chemotherapy agents was investigated, showing remarkable resistance to
chemotherapy-induced apoptosis in ARO/CD133pos when compared with ARO/CD133neg cells.
Conclusions/Significance: We describe CD133pos cells in ATC cell lines. ARO/CD133pos cells exhibit stem cell-like features -
such as high proliferation, self-renewal ability, expression of OCT-4 - and are characterized by higher resistance to
chemotherapy. The simultaneous positivity for thyroid specific factor TTF-1 and onfFN suggest they might represent
putative thyroid cancer stem-like cells. Our in vitro findings might provide new insights for novel therapeutic approaches.
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Introduction
Anaplastic thyroid carcinoma (ATC) is one of the most
aggressive endocrine tumors with morphological features of
undifferentiated neoplasm. Patients with ATC have a poor
prognosis with a mean survival time of 2–6 months. Surgery,
radiotherapy and chemotherapy do not improve survival rate [1].
Recently, adult stem cells were identified in human thyroid
glands [2]. These cells express several specific markers, such as the
nuclear transcription factor OCT-4 (also known as OCT-3, OCT-
3/4) and the endodermal markers GATA-4 and HNF4a [2–4].
A link between stem and cancer cells has been suggested in
various tissues where cancer cells are supposed to derive from
immature progenitors or stem cells [5]. Cancer stem cells (CSCs)
have been found in leukemia [6], glioblastoma [7], breast [8],
prostate [9], gastric [10], lung [11], and colon [12] cancer. These
cells, which represent only a small population within the bulk of
the tumor, possess the simultaneous ability to self-renew and
differentiate into other cytotypes [13]. The stem-like phenotype
has proved to be capable of resisting conventional therapies, thus
leading to disease relapse even when the primary lesion has been
eradicated [14,15]. To date, however, no studies have definitely
indicated that stem cells are responsible for thyroid carcinogenesis.
However, the rarity and rapid growth pattern of ATC resembles
the nature of stem cells. Only one study has described a very small
population, termed side population, enriched for stem cells among
thyroid cancer cell lines [16]. In addition, the hypothesis of fetal
cell carcinogenesis, in which cancer cells are derived from the
remnants of fetal thyroid cells instead of adult thyrocytes, has been
proposed [17].
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Several markers have been identified for the characterization of
CSCs. Human CD133, a highly conserved antigen homologue of
mouse Prominin-1, was originally identified in a subpopulation of
CD34+ hematopoietic cells derived from human fetal liver and
bone marrow [18–19]. CD133 has been used for the identification
and isolation of a putative CSC population from several human
cancers [20,21]. In addition, the expression of CD133pos CSCs in
hepatocellular carcinoma (HCC) was shown to confer chemore-
sistance in vitro [14]. However, its biological function remains
unknown. The transcription factor OCT-4 is considered a main
regulator of human embryonic stem cell pluripotency and self-
renewal capacities [22]. Interestingly, these stem-cell properties
are attributed to OCT-4A, a splice variant of the OCT-4 gene
located in the nucleus [23,24].
The aim of the present study was to investigate the expression of
putative stem cell markers in established human ATC cell lines, such
as ARO, KAT-4, KAT-18 and FRO. We identified CD133pos cells
in ARO and KAT-4 cell lines. This subset was characterized by
higher in-vitro proliferation, self-renewal and colony forming ability.
ARO/CD133pos were more resistant than ARO/CD133neg cells to
chemotherapy-induced apoptosis. In addition, ARO/CD133pos cells
expressed the thyroblast specific transcription factor TTF-1 and the
stem cell marker OCT-4, whereas they were negative for the stem
cell markers c-Kit and THY-1.
Materials and Methods
Cell lines and culture conditions
Human ATC cell lines ARO, KAT-4, KAT-18 and FRO were
kindly provided by Prof. A. Fusco, University of Naples, Italy.
During expansion phase and for self-renewal assay cells were
cultured in RPMI 1640 medium containing 10% heat-inactivated
fetal bovine serum (FBS). For all other experiments, cells were
cultured in RPMI1640 serum free medium (SFM), supplemented
with basic Fibroblast Growth Factor (bFGF, 20 ng/ml; Sigma-
Aldrich, St. Louis, MO, USA) and Epidermal Growth Factor
(EGF, 20 ng/ml; Sigma-Aldrich) [25].
Flow Cytometry
The expression of stem cell markers CD133, OCT-4, c-Kit and
THY-1 was evaluated by flow cytometry (FACSCalibur, Becton
Dickinson, San Jose, CA, USA). For CD133 analysis, cells were
first treated with FcR blocking reagent (Miltenyi Biotec, Bergisch
Gladbach, Germany) and then incubated in the dark at 4uC for
10 minutes with phycoerythrin (PE)-conjugated mouse IgG2b anti
human CD133/2 (clone 293C3, Miltenyi Biotec). For co-staining
with c-Kit and THY-1, cells were subsequently incubated with
monoclonal mouse IgG1 anti-human c-KIT and mouse IgG1 anti-
human THY-1 antibodies (Chemicon International, Temecula,
Ca, USA) at 4uC for 30 minutes. Cells were washed twice with
PBS and then incubated with fluorescein isothiocyanate (FITC)-
conjugated polyclonal goat anti-mouse at 4uC for 30 minutes. For
staining with OCT-4, cells were fixed and permeabilized with
Cytofix-Cytoperm kit (BD Pharmingen, San Diego, Ca, USA)
according to the manufacturer’s instructions. Cells were then
incubated with monoclonal mouse IgG2b anti-human OCT-3/4
(Santa Cruz Biotechnology, Santa Cruz, Ca, USA) at 4uC for
30 minutes, washed twice with PBS and incubated with
phycoerythrin (PE)-conjugated polyclonal goat anti-mouse at
4uC for 30 minutes. The primary antibody recognizes the OCT-
4A isoform of the protein (aa 1–134).
Apoptosis was evaluated by caspase 3 assay. Cells were first
fixed and permeabilized with Cytofix-Cytoperm kit (BD Pharmin-
gen, San Diego, Ca, USA) according to the manufacturer’s
instructions. Cells were then incubated with monoclonal IgG
rabbit anti-Active Caspase 3 (BD Pharmingen) at room temper-
ature for 20 minutes, washed twice with PBS and then incubated
with fluorescein isothiocyanate (FITC)-conjugated polyclonal goat
anti-rabbit IgG (Santa Cruz Biotechnology) at room temperature
for 20 minutes.
Data were analyzed with CELLQuest Pro software (Becton
Dickinson Immunocytometry Systems, San Jose, CA, USA). Gating
was implemented based on negative control staining profiles.
Immunocytochemistry
ARO and KAT-4 cell lines were plated in chamber slides (Lab-
Tek, Nunc, Inc. Naperville, USA), allowed to attach for 48 hours
and then used for immunocytochemistry. Cells were fixed in 3%
H2O2 in methanol for 10 minutes at room temperature, then
washed twice in PBS, blocked with 3% BSA and permeabilized with
PBS containing 0.1% Triton X-100 for 10 minutes at room
temperature. Cells were incubated with mouse anti-human CD133
(IgG1, clone AC133,Miltenyi Biotec) in blocking buffer for 1 hour at
room temperature, then rinsed with PBS. Expression was detected
using secondary biotinylated antibodies and streptavidin/horserad-
ish peroxidase. Chromogen 3-amino-9-ethylcarbazole (AEC) sub-
strate was used and slides were counterstained with hematoxylin.
Sorting of ARO/CD133pos cells
ARO cells were trypsinized and labeled with primary CD133-
Biotin and Biotin-Microbeads (Indirect CD133 cell Isolation Kit,
Miltenyi Biotec), according to the manufacturer’s instructions.
After magnetic sorting, cell purity was evaluated by flow cytometry
using phycoerythrin (PE)-conjugated anti-human CD133/2 (clone
293C3, Miltenyi Biotec).
Isolation of total RNA, RT-PCR and qRT-PCR
Total RNA was extracted and purified from cultured KAT-4,
KAT-18, FRO and ARO (unsorted, sorted CD133neg and
CD133pos) cell lines using RNeasy Mini Kit (Qiagen, Milan,
Italy), including a digestion step with DNase I set. RNA quantity
and quality were assessed by UV spectrophotometry. 2 mg total
RNA were reverse transcribed in a volume of 20 ml with Oligo dT
primers (Applied Biosystems, Darmstad, Germany) and Strata-
script RT (Stratagene, Amsterdam, Netherland), according to the
manufacturer’s protocol. Thyroglobulin (Tg), thyroperoxidase
(TPO), sodium/iodide symporter (NIS), oncofetal fibronectin
(onfFN) and OCT-4 expression was analyzed by polymerase
chain reaction (PCR) [26–27]. 1 ml complementary DNA was
added to 50 ml reaction containing 5 ml 106 reaction buffer,
50 mmol/L MgCl2, 1 ml dNTPs, 50 pmol sense and antisense
primers and 0.5 U Taq Gold DNA polymerase. Reactions were
carried out at 95uC for 10 minutes; 35 cycles at 95uC for
45 seconds, 55uC for 45 seconds (primer specific) and 72uC for
45 seconds, followed by an extension at 72uC for 7 minutes and
termination at 4uC. Primer pair sequences, cDNA fragment sizes
and annealing temperatures were as follows: Tg (762 bp): 59-
CTTCGAGTACCAGGTTGATGCC-39 and 59-GGTGGTTT-
CAGTGAAGGTGGAA-39 (55uC), TPO (593 bp): 59-TGTGTC-
CAACGTGTTCTCCACAG-39 and 59-AAGACGTGGCTGT-
TCTCCCAC-39 (55uC), NIS (179 bp): 59-CTATGGCCTCAA-
GTTCCTCT-39 and 59-TCGTGGCTACAATGTACTGC-39
(57uC), onfFN (215 bp): 59-TCTTCATGGACCAGAGATCT-39
and 59-TATGGTCTTGGCTATGCCT-39 (55uC), OCT-4
(456 bp): 59-AGCCCTCATTTCACCAGGCC-39 and 59-TGG-
GACTCCTCCGGGTTTTG-39 (63uC), b-actin (439 bp): 59-GA-
TGACCCAGATGACCCAGATCATGTTTG-39 and 59-AGG-
CTGGAAGAGTGCCTCA-39 (55uC). For OCT-4 analysis,
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Figure 1. Expression of CD133 in ATC cell lines. (A) Flow cytometry analysis of CD133 in ARO, KAT-4, KAT-18, and FRO cell lines. Black lines
represent positive staining for CD133, grey lines show negative control with matched isotype antibody. Data are representative of three independent
experiments. (B) Analysis of CD133 expression in ATC cell lines by qRT-PCR. Data are represented as fold change (relative scale), considering KAT-
18 = 1. (C) Immunocytochemistry of CD133 in ARO cell line. Arrows indicate apical and polarized localization of CD133 (206magnification).
doi:10.1371/journal.pone.0003544.g001
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nTERA2 cDNA (positive control) was kindly provided by Dr. S.
Liedtke, University of Dusseldorf, Germany. For onfFN and TTF-
1, TAD-2 cDNA was used as positive control. CD133 and TTF-1
expression was analyzed by real-time quantitative PCR (qRT-
PCR) in individual samples. Total 2 mg were used to measure
mRNA levels relative to b-actin mRNA expression. PCR primers
and probes were purchased from Qiagen (Quantitect Primer
Prominin1 and TTF1). All reactions were performed in a final
volume of 20 ml with 2 ml cDNA template using a LightCycler
(Roche Diagnostics GmbH, Germany). Data analysis was performed
with qBASE Browser which employs a D-Ct relative quantification
model with PCR efficiency correction and single reference gene
normalization (b-actin: 59-GGACTTCGAGCAAGAGATGG-39,
and 59-AGCACTGTGTTGGCGTACAG-39) [28].
In Vitro Culture and Cell Proliferation Assay of ARO/
CD133pos cells
After isolation, ARO/CD133pos and ARO/CD133neg cells
were cultured immediately in SFM supplemented with bFGF and
EGF in an atmosphere of 5% CO2 at 37uC.
Cell proliferation was assessed by colorimetric assay using 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and
BrdU (colorimetric) kit (Roche Diagnostics GmbH, Germany). For
MTT assay, sorted ARO/CD133pos and ARO/CD133neg cells were
plated in a 96-well plate in 100 ml SFM/well and cultured up to
72 hours. Cells were incubated for 4 hours at 37uC with MTT; after
incubation, medium was removed and cells were treated with
DMSO for 5 minutes. Viability was evaluated by UV absorption
spectrum at 550 nm with Microplate Reader Model 550 (Bio-Rad,
Richmond, CA, USA).
For BrdU assay, sorted ARO/CD133pos and ARO/CD133neg
were plated in a 96-well plate in 100 ml SFM/well and cultured up
to 144 hours. Viability was evaluated by UV absorption spectrum
at 450 nm with Microplate Reader Model 550 (Bio-Rad,
Richmond, CA, USA).
Self-Renewal Assay of ARO/CD133pos cells
Sorted ARO/CD133pos cells were cultured in RPMI 1640
supplemented with 10% FBS. CD133 expression was detected by
flow cytometry on days 0, 4, 8 and 11. At the same time points
apoptosis was assessed by Annexin V-FITC Apoptosis Detection
Kit (BD Pharmingen, San Diego, Ca, USA) following the
manufacturer’s instructions.
Colony formation assay of ARO/CD133pos cells
Sorted ARO/CD133pos and ARO/CD133neg cells were
cultured in 6-well plates in methylcellulose SFM (HSC-CFU basic
medium, Miltenyi Biotec). Plates were maintained at 37uC in a
humidified incubator for 2 weeks. The number of colonies was
assessed by microscopic counting.
Chemotherapy agents
ARO/CD133pos and CD133neg cells were cultured in SFM
supplemented with bFGF (20 ng/ml) and EGF (20 ng/ml) with or
without cisplatin (5, 10, 15 and 20 mM; Pharma, Austria),
doxorubicin (0.5, 1, 1.5 and 2 mM; Ebewe Pharma, Austria),
etoposide (10, 30, 100 mM; Teva Pharma, Netherland). The
percentage of viable ARO/CD133pos and CD133neg cells was
evaluated at 24, 48 and 72 hours by MTT assay and at 48, 96 and
120 hours by BrdU assay.
For apoptosis evaluation, ARO/CD133pos and CD133neg cells
were cultured in 6-well plates and treated with the highest
concentration of each drug (20 mM cisplatin, 2 mM doxorubicin
and 100 mM etoposide) up to 120 hours. Apoptosis evaluation
(caspase 3 assay) was assessed by flow citometry as described
above.
Statistical analysis
Statistical analysis was performed with SPSS v. 11 software for
Windows. Data are expressed as mean6SD. Statistical compar-
isons were based on nonparametric tests and statistical significance
was defined at p,0.05. For experiments with chemoterapics,
differences in viability of ATC cell lines were calculated with the
Mann-Whitney test; p for trend with different drug concentrations
was calculated with the W of Kendall test.
Results
Identification of CD133pos cells in ATC cell lines
In order to identify CSCs in ATC cell lines, we analyzed the
expression of CD133 by flow cytometry in ARO, KAT-4, KAT-
18 and FRO (Fig 1A). ARO and KAT-4 showed a mean positivity
of 6469% and 57612%, respectively; KAT-18 and FRO were
negative. Results were confirmed by qRT-PCR (Fig. 1B).
CD133pos cells in ARO cell lines were characterized by
cytoplasmatic and polarized localization of the antigen on the
apical surface of the cells (Fig. 1C). The undifferentiated status of
ATC cell lines was confirmed in PCR by the presence of onfFN
[26] and the absence of thyrocyte-specific differentiating markers
Tg, TPO and NIS [27] (Fig. 2A and B).
Figure 2. Undifferentiated status of ATC cell lines. Expression of
thyroid specific genes (Tg, TPO, NIS) (A) and fetal marker onfFN (B) in
ARO, KAT-4 and normal thyroid by RT-PCR. TAD-2 cell line was used as
positive control for onfFN mRNA. b-actin was used as internal control in
both experiments. bp=base pairs.
doi:10.1371/journal.pone.0003544.g002
CD133 in ARO Cell Line
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Cell culture of sorted ARO/CD133pos cells
Cluster-forming efficiency of sorted ARO/CD133pos cells was
evaluated by FACS analysis, showing 90% CD133 positivity
(Fig. 3A). After isolation, ARO/CD133pos cells, cultured in SFM
supplemented with bFGF and EGF, grew as single, non-adherent,
spherical cells. After a few days, ARO/CD133pos cells started to
form clusters which progressively increased in number and size,
although they did not form follicles. On the contrary, ARO/
CD133neg cells scarcely aggregated in clusters (Fig. 3B).
In vitro cell proliferation assay, self-renewal and colony-
forming capacity of ARO/CD133pos cells
Proliferation was evaluated by MTT and BrdU assay. ARO/
CD133pos cells showed in vitro increased proliferation in comparison
to ARO/CD133neg cells with both MTT at 48–72 hours and BrdU
at 72–144 hours (p= 0.028 and p#0.001, respectively) (Fig. 4A and
B). As regards caspase 3, flow cytometry showed spontaneous
apoptosis in SFM, which ranged after 144 hours from 0.5 to 2% for
ARO/CD133pos cells and from 3.4 to 8.8% for ARO/CD133neg
cells (data not shown). Self renewal was also assessed (Fig. 4C).
CD133 expression on ARO/CD133pos cells initially decreased from
90% on day 0 to 46% on day 8, and maintained a steady state until
day 11. The decrease in CD133 expression overtime was not caused
by cell death (,2%, data not shown). Instead, cell proliferation
continued for the entire culture period, suggesting that ARO/
CD133pos cells are characterized by asymmetrical division ability (i.e.
production of two daughter cells, one CD133pos and one CD133neg).
Colony-forming assay confirmed the high self-renewal ability of
ARO/CD133pos, in comparison to ARO/CD133neg cells. In fact,
ARO/CD133pos cells were able to form a higher number of tumor
colonies (p= 0.028) (Fig. 4D and 4E).
Treatment of ARO/CD133pos and CD133neg cells with
chemotherapy drugs
Drug sensitivity was evaluated by MTT and BrdU assay. ARO/
CD133pos and ARO/CD133neg cells were incubated with different
concentrations of doxorubicin, cisplatin and etoposide. ARO/
CD133pos cells showed a remarkable drug resistance to the three
agents compared with ARO/CD133neg cells during the entire
culture period (p#0.05 for MTT and p#0.001 for BrdU,
respectively). One representative experiment after 48 hours of each
treatment is shown in Fig. 5A–F. Consistently with these findings,
apoptosis assessed by caspase 3 activity showed a dramatic activation
in ARO/CD133neg in comparison to ARO/CD133pos cells at all
Figure 3. Cluster-forming efficiency of sorted ARO/CD133pos cells. (A) Purity of ARO/CD133pos cells after magnetic cell sorting assessed by
flow cytometry. (B) Characteristics of sorted ARO/CD133pos and ARO/CD133neg on days 0, 3 and 10 of culture. ARO/CD133pos cells formed clusters
which increased in size overtime.
doi:10.1371/journal.pone.0003544.g003
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time points analyzed (Figure 6A, representative of three independent
experiments with doxorubicin). Histograms at time point 72 hours
are shown in Figure 6B. Similar results were obtained with the other
drugs used (data not shown).
In vitro characterization of ARO/CD133pos cells
In order to further characterize the ARO/CD133pos popula-
tion, we evaluated the co-expression of other stem cell markers.
The mRNA expression of thyroid transcription factor-1 (TTF-1) in
ARO/CD133pos was significantly higher than in ARO/CD133neg
cells, similar to TAD-2 fetal thyroid cell line (positive control)
(Fig. 7A). OCT-4 expression was 9163% in ARO/CD133pos cells
vs 561.5% in ARO/CD133neg, suggesting the pluripotent stem
cell features of ARO/CD133pos cells (Figure 7B). These data were
confirmed by semiquantitative PCR, using nTERA2 cell line as
positive control (Figure 7C). Quantification, expressed as relative
to nTERA2 density, showed OCT-4 mRNA levels in ARO/
CD133neg cells almost two fold lower than in ARO/CD133pos
(35% vs 62% respectively, with nTERA2=100%).
The membrane stem cell markers c-Kit - expressed in ESCs
(embryonic stem cells) - and THY-1 - typical of mesenchymal and
hematopoietic stem cells - were negative (data not shown).
Discussion
In the last few years several studies have been published
supporting the hypothesis that tumors arise from heterogeneous
cell populations with different biological properties. Recently, it
has been suggested that stem cells, characterized by self-renewal
and differentiation ability, may play a role in cancer development
[29,30]. Since multiple mutations occurring over many years are
necessary before a cell becomes cancerous, stem cells with a long
Figure 4. Proliferation, self-renewal and colony-forming capacity of ARO/CD133 cells. (A) Cell proliferation assay (MTT). Dotted line
represents ARO/CD133neg cells, continuous line represents ARO/CD133pos cells. Data are expressed as mean values6SD and are representative of four
independent experiments. p,0.03. (B) Cell proliferation assay (BrdU). Dotted line represents ARO/CD133neg cells, continuous line represents ARO/
CD133pos cells. Data are expressed as mean values6SD and are representative of four independent experiments. p#0.001. (C) Self-renewal ability of
ARO/CD133pos cells. Black line represents number of ARO/CD133pos cells assessed by flow cytometry. Dotted line represents cell viability assessed by
MTT assay. (D) Colony formation assay in methylcellulose medium of sorted ARO/CD133pos and CD133neg cells (406magnification) (E) Number of
colonies of ARO/CD133pos and CD133neg cells after 15 days of incubation (p,0.03).
doi:10.1371/journal.pone.0003544.g004
CD133 in ARO Cell Line
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life-span may be the best candidates for accumulating such cancer-
inducing heterogeneous cells [5,31]. However, it is not clear yet
whether or not these CSCs originate from dedifferentiation of
mature cells within the organs or from resident stem cells which
progressively acquire a malignant phenotype [32].
ATC is one of the most aggressive endocrine tumors
characterized by high degree of dedifferentiation [1]. The
existence of resident thyroid stem cells may account for both the
sustained proliferation and heterogeneity of ATC lesions [4].
Takano et al. hypothesized that a close relationship between stem
cells and carcinogenesis might exist in ATC [17,26,33]. ATC gene
expression profile suggested at least three types of undifferentiated
cells as its origin: thyroid stem cells, expressing onfFN mRNA but
not Tg, with high differentiation potential, self-renewal and ability
to generate anaplastic carcinomas; thyroblasts, expressing both Tg
and onfFN mRNA and not forming follicles; prothyrocytes, which
are more differentiated than thyroblasts, expressing Tg but not
onfFN mRNA, with the ability to form follicles. Mitsutake et al.
have identified a very small side population (SP), highly enriched
for stem cells, in several human thyroid cancer cell lines. However,
both SPpos and SPneg populations formed tumors when trans-
planted in nude mice, demonstrating that cancer stem-like cells are
not exclusive or identical to SP cells [16].
In the present study, we ourselves maintain that ATC may
originate from thyroid stem cells. We describe CD133pos cells with
phenotypical characteristics of stem cells, growing without forming
follicles. However, among the four cell lines analyzed, only ARO
and KAT-4 showed high percentage of CD133pos cells (6469%
and 57612%, respectively; Fig. 1A). Our results are consistent
with recent observations on highly aggressive hepatoma cell lines,
Figure 5. Sensitivity of ARO/CD133pos and ARO/CD133neg cells to chemotherapy agents. (A) MTT analysis after 48 hours of culture in the
presence of 0.5, 1, 1.5 and 2 mM doxorubicin (B) after 48 hours in the presence of 5, 10, 15 and 20 mM cisplatin (C) after 48 hours in the presence of
10, 30 and 100 mM etoposide. Data are expressed as mean values6SD and are representative of three independent experiments (p#0.05). (D) (E) (F)
represent BrdU analysis in the same conditions of A, B, C (p#0.001). Dotted line represents ARO/CD133neg cells and continuous line represents ARO/
CD133pos cells in all graphs.
doi:10.1371/journal.pone.0003544.g005
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also characterized by very high percentage of CD133pos cells [34].
High CD133 expression in ATC might be therefore associated
with tumor aggressiveness. However, the absence of this marker in
KAT-18 and FRO cell lines, suggests that the mere presence of
CD133 is not sufficient and other markers still need to be
identified. In addition, as reported by Takano et al. [17], we found
that ARO and KAT-4 cell lines expressed onfFN but not Tg, TPO
and NIS, confirming their undifferentiated status.
To better characterize the functional and phenotypic features of
these putative CSCs in ATC, we studied sorted ARO/CD133pos
cells. ARO/CD133pos cells showed higher cell proliferation rate
in comparison to CD133neg cells (Fig. 4A and B). Furthermore, the
self-renewal ability of ARO/CD133pos cells was confirmed by
decrease in CD133 expression parallel to increase in cell
proliferation, thus suggesting asymmetric division, i.e. production
of CD133pos and CD133neg daughter cells. However, mechanisms
other than asymmetric division (e.g. CD133 post-transcriptional
down-regulation) cannot be excluded. Minimal cell death percent-
ages exclude that the decrease in CD133 expression was due to
apoptosis (,2%).
Further confirmation that most of the ARO/CD133pos cells
may be stem/progenitor cells comes from expression analysis of
other genes related to ‘‘stemness’’. Although the stem cell markers
c-Kit and THY-1 were negative, a strong positivity was found for
OCT-4. OCT-4 belongs to the POU (Pit-Oct-Unc) family of
transcription factors which mediates pluripotency in ESCs through
the inhibition of tissue-specific and promotion of stem-cell genes
[22,23]. ARO/CD133pos sorted cells were strongly positive for
OCT-4A in comparison to ARO/CD133neg cells, and their
expression was similar to that of nTERA2 embryonic teratoma cell
line. The primers and the monoclonal antibody used in our
experiments for the nuclear splicing variant OCT-4A exclude any
pseudogene contamination or artifacts [24].
The nuclear thyroid specific transcription factor TTF-1 is a
homeodomain-containing protein belonging to the Nkx-2 class of
homeobox genes, which is required for proper thyroid develop-
ment and is used as a marker of thyroid and lung carcinoma [35].
TTF-1 expression was found significantly higher in ARO/
CD133pos than in ARO/CD133neg cells, with mRNA levels
comparable to TAD-2 fetal thyroid cell line (positive control). This
Figure 6. Flow cytometry analysis of caspase 3 in ARO/CD133pos and ARO/CD133neg cells after treatment with chemotherapy
agents. (A) Caspase 3 activity after treatment with doxorubicin. Dotted line represents ARO/CD133neg cells, continuous line represents ARO/
CD133pos cells. Data are expressed as mean6SD (p#0.001). (B) Caspase 3 activity at time point 72 hours with doxorubicin. Black line represents
positive staining for caspase 3, grey line shows negative control with matched isotype antibody. Data are representative of three independent
experiments.
doi:10.1371/journal.pone.0003544.g006
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implies that although all ATC cell lines are dedifferentiated (absent
expression of thyroid-specific genes such as Tg, TPO and NIS and
positivity for onfFN), in ARO/CD133poscells a marker of thyroid
organogenesis is still maintained.
Furthermore, in order to functionally characterize these
putative cancer stem-like cells, we tested sensitivity to the most
common chemotherapy drugs used in ATC, i.e. cisplatin,
doxorubicin and etoposide. Cisplatin crosslinks DNA in several
different ways interfering with cell division by mitosis, doxorubicin
interacts with DNA by intercalation and inhibition of macromo-
lecular biosynthesis and etoposide inhibits the enzyme Topoisom-
erase II [36–38]. ARO/CD133pos cells revealed a significant
resistance to all drugs used at each time point in comparison to
ARO/CD133neg cells, as demonstrated by markedly lower
apoptosis levels detected via caspase 3 (Fig. 6). The potential
induction of antiapoptotic rather than apoptotic molecules, or the
blockage of thyrocyte physiological cell-turnover regulatory
mechanisms, demonstrated in other thyroid diseases, such as
autoimmune thyroiditis [39], might explain the acquired capabil-
ity of thyroid stem-like cells to become resistant to chemotherapy.
As shown in glioblastomas, a better comprehension of the
mechanisms allowing ARO/CD133pos cells to resist conventional
therapies may help to find ways to manipulate them to become
sensitive to these properties [40].
Our study suggests the existence of cancer stem-like cells in
ATCs. However, because there is no unanimous consent about the
existence of thyroid stem cells or CSCs in human thyroid, the
precise nature of such cells still remains to be established [41].
Schweppe et al. [42] recently questioned the use of thyroid cell
lines for identification of molecular aspects involved in carcinogen-
esis and particularly of ARO 81-1 and KAT-4 cell lines. However,
ARO and KAT-4 cell lines used in our experiments, expressed
thyroid specific factors TTF-1 and onfFN, confirming their thyroid
origin. In addition, PAX8 was also positive (data not shown).
A conclusive answer might derive from in vivo experiments in
nude mice. However xenograft transplantation by itself may fail to
identify true cancer initiating human cells that are not conducive
to growth in a non-permissive mouse microenvironment, as
recently suggested by Shmelkov et al. [43]. CD133neg cells from
metastatic colon cancer were shown to initiate tumors when
injected in NOD/SCID mice, challenging the dogma that
CD133pos derived from human colon carcinomas are the only
cells that could initiate tumor in xenograft models. Indeed, the
existence of a high heterogeneity of tumorigenic factors could
explain the negativity of KAT-18 and FRO cell lines for CD133.
Nevertheless, our preliminary data with immunohistochemical
analysis in 5 ATC specimens showed variable positivity for CD133
in all the samples analyzed (personal observations, not published).
These results warrant further investigation on large numbers to
definitely confirm CD133 expression in all ATC ex vivo specimens.
In conclusion, our study may contribute to the elucidation of
thyroid carcinogenetic mechanisms in ATC, providing new
insights for novel therapeutic approaches.
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